Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 4/20 | 0.34 |
| ▸ | TDO2 | P48775 | 4/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080374 | 0.90 | SSTR2 (0.37) | CYP19A1SLC2A1KCNH2SSTR2 | |
| SCHEMBL5746846 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL5746857 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL5747963 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL5746855 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL5747952 | 0.85 | SLC2A1 (0.46) | SLC2A1KCNH2 | |
| SCHEMBL6080089 | 0.85 | SSTR2 (0.44) | SLC2A1KCNH2SSTR2GRM5 | |
| SCHEMBL6080508 | 0.83 | SLC2A1 (0.40) | SLC2A1KCNH2IDO1TDO2CYP2C8 | |
| SCHEMBL6080502 | 0.83 | SLC2A1 (0.40) | SLC2A1KCNH2IDO1TDO2CYP2C8 | |
| Dioxane SCHEMBL5745626 | 0.81 | SLC2A1 (0.46) | SLC2A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CYP19A1 3878/4885SLC2A1 4409/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.